High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma

Abstract Background MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype of sporadic RCC that is predominantly seen in young patients and can...

Full description

Bibliographic Details
Main Authors: Martin Lang, Laura S. Schmidt, Kelli M. Wilson, Christopher J. Ricketts, Carole Sourbier, Cathy D. Vocke, Darmood Wei, Daniel R. Crooks, Youfeng Yang, Benjamin K. Gibbs, Xiaohu Zhang, Carleen Klumpp-Thomas, Lu Chen, Rajarshi Guha, Marc Ferrer, Crystal McKnight, Zina Itkin, Darawalee Wangsa, Danny Wangsa, Amy James, Simone Difilippantonio, Baktir Karim, Francisco Morís, Thomas Ried, Maria J. Merino, Ramaprasad Srinivasan, Craig J. Thomas, W. Marston Linehan
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
MiT family translocation RCC
TFE3-RCC
TFE3-fusion
GPNMB
RCC therapy
NVP-BGT226
Online Access:https://doi.org/10.1186/s13046-023-02667-4

Internet

https://doi.org/10.1186/s13046-023-02667-4

Similar Items